LSE
Every company in the roster listed on LSE.
Every company in the roster listed on LSE.
1 of 1 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Hikma Pharmaceuticals PLCHIK · LSE | 3 assets: 3 approved | Approved assets only | 31 Jan 2027Cenobamate · Phase 2 | — | $217MDec 2025 | Profitable | $151M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.